

ARTICLE

Received 22 Feb 2013 | Accepted 3 Sep 2013 | Published 4 Oct 2013

DOI: 10.1038/ncomms3546

Structure of GrIR–GrIA complex that prevents GrIA activation of virulence genes

Abhilash Padavannil¹, Chacko Jobichen¹, Erez Mills², Adrian Velazquez-Campoy^{3,4,5}, Mo Li¹, Ka Yin Leung^{6,7}, Yu Keung Mok¹, Ilan Rosenshine² & J. Sivaraman¹

The *locus of enterocyte effacement* (*LEE*) is essential for virulence of enterohaemorrhagic *Escherichia coli* (EHEC) and enteropathogenic *E. coli* (EPEC). The 41 genes of the *LEE* encode type III secretion system proteins and three associated regulators: Ler, GrIA and GrIR. Ler is a positive regulator for most of the *LEE* operons, including *grlRA*. GrIA controls the expression of *ler*, *ehxCABD* and *flhDC* operons. GrIR binds to GrIA and suppresses its function. Here we report the crystal structure of GrIR–GrIAΔ (aa 1–106) complex (2:1) and its functional characterization. We show that GrIR interacts with the Helix–Turn–Helix motif of GrIA. Moreover, GrIA binds to the promoter DNA fragments of *ler*, *ehxCABD* and *flhDC*, and GrIR outcompetes with these promoter DNA sequences for the Helix–Turn–Helix motif of GrIA. These findings provide mechanistic insight into a regulatory module for the virulence of EPEC and EHEC, two important pathogens that cause devastating diseases.

¹ Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543, Singapore. ² Faculty of Medicine, Department of Microbiology and Molecular Genetics, IMRIC, The Hebrew University, Jerusalem 91120, Israel. ³ Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint-Unit IQFR-CSIC-BIFI, Zaragoza 50018, Spain. ⁴ Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza, Zaragoza 50009, Spain. ⁵ Fundacion ARAID, Government of Aragon, Zaragoza 50018, Spain. ⁶ Department of Biology, Trinity Western University, 7600 Glover Road, Langley, British Columbia, Canada V2Y 1Y1. ⁷ State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China. Correspondence and requests for materials should be addressed to J.S. (email: dbsjayar@nus.edu.sg).

Attaching and effacing (AE) pathogens comprise a group of enteric pathogens, including the closely related enterohaemorrhagic *Escherichia coli* (EHEC) and enteropathogenic *E. coli* (EPEC). EPEC causes severe diarrhea in young children, whereas EHEC is a causative agent of haemorrhagic colitis and haemolytic uremic syndrome^{1,2}. AE pathogens possess type III secretion systems (T3SS) that promote virulence. Most T3SS components and related proteins are encoded by genes in the locus of enterocyte effacement (LEE). The LEE consists of 41 genes, clustered in 5 different operons, termed *LEE1*–*LEE5*, and some additional transcription units³.

Under specific conditions, such as low temperature, the histone-like nucleoid-structuring (H-NS) protein binds to extended regions within the LEE DNA and silences the expression of the entire LEE region. This H-NS-mediated repression, however, can be countered by Ler (LEE-encoded regulator), a protein encoded by the first gene in the *LEE1* operon that functions as a positive regulator of other LEE operons (*LEE2*–*LEE5*)⁴. Moreover, Ler is involved in both the direct and indirect regulation of additional key virulence components of EPEC and EHEC, and is thus considered as the master regulator of the virulence machineries of these pathogens. Accordingly, activation of *LEE1* and *ler* expression is a key event in the activation of the entire virulence system of EPEC and EHEC. It is therefore not surprising that the *LEE1* promoter is subjected to tight regulation by multiple factors (Fig. 1), including H-NS and Ler, which function as repressor and autorepressor, respectively. The expression of the *LEE1* operon is strictly dependent on binding of the integration host factor protein immediately upstream to the *LEE1* promoter⁴, and activation of *LEE1* expression is promoted by two redundant positive regulators, PerC⁵ (or Pch in EHEC) and GrlA.

The *grlR* and *grlA* genes form a transcriptional unit encoding GrlR and GrlA, respectively. GrlA is a positive regulator of the *LEE1* promoter and forms a positive regulatory loop with Ler. GrlR binds to GrlA and this is thought to account for the negative effect of GrlR on *ler* expression^{3,4,6}. As GrlA and GrlR are co-expressed, it is expected that, in most cases, GrlA is inhibited by GrlR and that the relative levels of GrlR and GrlA are regulated. For instance, it was reported that under certain conditions GrlR is degraded by the ClpXP protease, freeing GrlA to activate Ler expression⁷.

Previously, we reported the structure of GrlR and elucidated its role in LEE regulation^{8,9}. GrlR forms a stable and tight dimer in solution as well as in the crystal. The dimeric architecture of GrlR is maintained by the cluster of hydrophobic interactions as well as numerous hydrogen-bonding contacts at the dimeric interface⁸. GrlA has also been functionally characterized^{3,4,10}, but no structural information is available to provide insight into the regulatory mechanisms involving GrlA, GrlR and Ler.

In addition to its function as a *LEE1* regulator, GrlA negatively regulates the transcription of the *flhDC* operon and thus controls flagellar gene expression. Kitagawa *et al.*¹¹ demonstrated that flagellar gene expression in EHEC was strictly regulated by dual pathways: (i) post-translational control of the FlhD/C master regulator by ClpXP-mediated protein degradation and (ii) transcriptional control of the *flhDC* operon through the GrlR–GrlA system under LEE-inducing conditions. Moreover, deletion of *grlR* results in a non-motile phenotype in the EHEC O157 Sakai strain⁶. In many pathogens, motility is repressed by negatively regulating *flhDC* concomitant with T3SS induction¹¹. GrlA-dependent repression of flagellar regulation is important for efficient adhesion of EHEC to host cells^{6,11} and perhaps also to avoid detection by the host innate immune sensors TLR5 and NLRP4 (refs 12,13). GrlA is also implicated in the transcriptional activation of the *ehxCABD* operon in EHEC^{14,15}. The *ehxA* gene encodes haemolysin, and *ehxC* acts as a modifying factor that




Figure 1 | Schematic of the regulatory circuits related to the GrlR–GrlA complex. We propose the following model based on results presented in this report as well as results previously published by others and by us. The *grlR* and *grlA* genes form a bicistronic operon located within the LEE. Under non-inducing conditions, the expression of the entire LEE, including *grlR*, is suppressed by a H-NS protein, and the activity of the residual GrlA is suppressed by GrlR via direct interaction (repression is indicated by red lines). The expression of the entire system can be activated by two alternative modes. The first involves specific environmental cues that turn on PerC expression; this, in turn, activates the expression of *ler* (activation is indicated by blue lines). Ler then antagonizes H-NS and stimulates the expression of all of the other LEE operon components, including *grlR*. The produced GrlA directly activates *ler* expression to establish the GrlA–Ler-positive feedback loop. Consequently, GrlA indirectly promotes the expression of all LEE genes, directly activates the expression of the *ehx* operon, and represses the expression of the flagella master regulator *flhDC*. The GrlA–Ler loop is restrained by the autorepressive action of Ler as well as by GrlR, which directly binds to GrlA to inhibit its interaction with target DNA. The second mode of activation involves environmental signals that trigger the ClpXP protease to degrade GrlR, thus releasing GrlA to activate *ler* expression and mediate the establishment of the Ler–GrlA-positive loop described above.

converts inactive haemolysin into its active form by the addition of a fatty acid group¹⁶; the specific secretion machinery for EhxA is encoded by *ehxB* and *ehxD*¹⁷.

The *in vitro* instability of GrlA has previously hindered structural studies and other attempts to elucidate the regulatory mechanism involving Ler, GrlA and GrlR. Here we report the crystal structure of GrlAΔ (aa1–106) in complex with GrlR, refined up to 2.7 Å resolution, and the associated functional studies. The structure is asymmetric with a stoichiometry of 2 GrlR:1GrlAΔ. In addition, we identify a novel regulatory mechanism by which GrlR interacts with GrlA at its Helix–Turn–Helix (HTH) motif, preventing GrlA from binding to its target promoter DNA.

Results

Overall structure of the GrlR–GrlAΔ complex. We initially attempted to determine the structure of full-length GrlA in complex with GrlR. However, the full-length GrlR–GrlA complex did not yield diffraction quality crystals, presumably because of the unstable nature of GrlA. As a result, we generated GrlR–GrlA complexes with varying lengths of GrlA. A complex of GrlR with GrlAΔ (aa1–106) (Fig. 2a) yielded diffraction quality crystals. The structure was determined and refined up to 2.7 Å resolution




Figure 2 | Structure of the GrIR-GrIAA heterotrimeric complex. (a) GrIR and GrIA proteins with motifs. (b) Crystal structure of the GrIR-GrIAA complex. The two monomers of GrIR are shown in green (monomer A) and cyan (monomer B). GrIAA is shown in magenta. The ligand Triton X-100 is shown as sticks. (c) Structure of GrIAA. (d) The topology diagram of the GrIAA molecule. Structure-related figures are prepared using PyMol³⁵. (e) The stoichiometric ratio of WT GrIR-GrIA complex protein was investigated in an analytical ultracentrifuge by monitoring their sedimentation properties in a sedimentation velocity experiment. The peak corresponds to a molecular weight of 47.3 kDa, indicating the presence of two molecules of 6His-GrIR and one molecule of GrIA in the complex.

(Table 1 and Fig. 2b). The first 8 residues and last 11 residues of GrIAA were not well-defined in the electron density map and were not included in the model. GrIR is a β -barrel protein, structurally similar to our previously determined GrIR structures (root mean squared deviation (r.m.s.d.) of 0.87 Å for all C_{α} atoms)^{8,9}, whereas GrIAA mainly comprises a HTH motif (aa 39–66) and an anti-parallel β -sheet in the carboxy terminus (Fig. 2c,d). The complex consists of one dimer of GrIR bound to a monomer of GrIAA (2:1 stoichiometric ratio), with 15 hydrogen-bonding contacts (<3.2 Å) formed between GrIR and GrIAA, and a buried area of 1,043.8 Å² (ref. 2). This GrIR:GrIA stoichiometric ratio was further verified by analytical ultracentrifugation, which showed that the complex is of 47.3 kDa, corresponding to two molecules of 6His-GrIR and one molecule of GrIA (Fig. 2e). This is consistent with the gel filtration experiment (Supplementary Fig. S1a,b).

Sequence and structural homology of GrIA. GrIA homologues are present in over 100 species of bacteria, including EPEC, EHEC, *Citrobacter rodentium*, *Shigella* sp. and *Salmonella* sp. with no structures available to date. GrIA shares 33% sequence identity (46% similarity) with CaiF, a potential transcriptional activator of carnitine metabolism in *E. coli*, and belongs to the PFAM family of DUF1401 (<http://pfam.sanger.ac.uk/family/DUF1401>). Despite a very low sequence identity ($<7\%$), the

DALI¹⁸ search for structural homologues of GrIA identified several regulatory proteins. The closest homologues are also HTH motif-containing proteins, such as a transcriptional regulator from *Methanosarcina mazei* (PDB 3R0A; r.m.s.d. 2.8 Å for 72 C_{α} atoms), a DNA-binding protein from *Pyrococcus horikoshii* OT3 (PDB 1ULY; r.m.s.d. 2.5 Å for 67 C_{α} atoms) and a double-stranded RNA-specific adenosine deaminase (PDB 3F23; r.m.s.d. 2.6 Å for 61 C_{α} atoms). These structural similarities suggest that these homologues may have similar functions, such as in transcriptional regulation.

GrIR interacts with the HTH and C-terminal regions of GrIA.

The crystal structure of the complex revealed that GrIR interacts with the HTH motif region of GrIAA (Fig. 3a,b and Supplementary Fig. S2a,b). The residues R53, R54, R64, R65 and K66 from the HTH region of GrIAA are involved in hydrogen-bonding contacts with GrIR. Our previous studies with GrIA⁸ suggested that the C-terminal region of GrIA might be involved in binding to GrIR (please refer to the Discussion section). Therefore, we sought to independently verify the contribution of the amino-terminal HTH motif and the C terminus of GrIA in its interaction with GrIR. To verify this, we created three constructs by substituting the abovementioned five interacting amino acids of the HTH motif region with alanine (denoted as GrIA5M), truncating the C-terminal region of GrIA

(GrIAΔ), or both mutations (GrIAΔ5M). Thus, the various GrIA constructs used in these interaction studies include MBP-GrIA, MBP-GrIA5M, MBP-GrIAΔ and MBP-GrIAΔ5M. The circular dichroism spectrum of the wild type (WT) and mutants of GrIA suggest that the mutants have the same fold as the WT GrIA (Supplementary Fig. S3).

The K_d for the interaction between GrIR and MBP-GrIA was determined by isothermal titration calorimetry (ITC). GrIR interacts with MBP-GrIA with an ~35-fold higher affinity

($K_d = 0.031 \mu\text{M}$) than with MBP-GrIAΔ ($K_d = 1.1 \mu\text{M}$) (Fig. 4a and Supplementary Table S1). Similarly, the K_d for the interaction between GrIR and MBP-GrIA5M was also higher ($K_d = 0.96 \mu\text{M}$) than the WT interaction (Fig. 4b and Supplementary Table S1). Besides the 35- and 31-fold reductions in affinity, respectively, MBP-GrIAΔ and MBP-GrIA5M also showed thermodynamic profiles distinct from the WT MBP-GrIA. Although the MBP-GrIA interaction with GrIR is enthalpically and entropically favourable ($\Delta H = -4.8 \text{ kcal mol}^{-1}$ and $-T\Delta S = -5.4 \text{ kcal mol}^{-1}$), the other two protein variants (GrIAΔ and GrIA5M) showed an enthalpically driven interaction, with unfavourable entropic contributions ($\Delta H = -21.0 \text{ kcal mol}^{-1}$ and $-T\Delta S = 12.9 \text{ kcal mol}^{-1}$, for MBP-GrIAΔ; $\Delta H = -9.6 \text{ kcal mol}^{-1}$ and $T\Delta S = 1.3 \text{ kcal mol}^{-1}$, for GrIA5M; Supplementary Table S1).

GrIR interacted with the WT MBP-GrIA or MBP-GrIAΔ with a stoichiometric ratio of 2:1. However, the stoichiometric ratio between GrIR and MBP-GrIA5M was 1:1, which suggests that two MBP-GrIA5M molecules bind with a dimeric GrIR (Supplementary Table S1). The MBP-GrIAΔ5M construct did not show binding to GrIR.

Subsequently, we examined the role of each of the aforementioned key residues in mediating the interaction between GrIR and GrIA by pull-down assay. MBP-GrIAΔ containing double amino acid substitutions (MBP-GrIAΔ (R53A R54A), MBP-GrIAΔ (R64A R65A) and MBP-GrIAΔ (R65A K66A)) did not interact with GrIR (Fig. 5a and Supplementary Figs S4a,b and S5a), whereas single alanine substitutions had little effect on the GrIAΔ–GrIR interaction (Supplementary Fig. S5b). Consistent with the ITC results, MBP-GrIA, MBP-GrIAΔ and MBP-GrIA5M pulled down GrIR, whereas MBP-GrIAΔ5M did not (Supplementary Fig. S5c). We further verified the role of the key residues of GrIR in mediating GrIA binding, which shows that alanine substitution at D35 and E60 of GrIR could abolish its binding to MBP-GrIAΔ (Fig. 5b and Supplementary Fig. S5d). Moreover, these results were confirmed using a pETDuet-1-*grIR-grIAΔ* co-expression and co-purification system with 6His tag on GrIR and a tagless GrIAΔ (Supplementary Figs S6a,b, S7 and S8). Taken together, these results show that GrIR–GrIA interaction involves both the HTH motif region and the C-terminal region of GrIA.

ler Promoter region and GrIR compete for HTH motif of GrIA. Previous studies demonstrated that GrIA binds to DNA via its HTH motif¹⁰, and the crystal structure of the GrIR–GrIAΔ complex revealed that GrIR interacts with the HTH motif region of GrIAΔ (Fig. 3a,b and Supplementary Fig. S2a,b). On the basis

Table 1 Crystallographic statistics and refinement details.	
SelMet SAD	
Data collection	
Space group	C222 ₁
Cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	<i>a</i> = 83.19, <i>b</i> = 121.21, <i>c</i> = 84.83
α , β , γ (°)	90
Wavelength	0.97893
Resolution (Å)	50.0–2.62(2.67–2.62)
R_{sym} or R_{merge}	0.12 (0.39)
<i>I</i> / σ <i>I</i>	16.23 (3.56)
Completeness (%)	98.0 (82.8)
Redundancy	13.9 (10.6)
Refinement	
Resolution (Å)	15.0–2.7
No. of reflections	22,108
$R_{\text{work}}/R_{\text{free}}$	0.18/0.23
No. of atoms	
Protein	2,543
Ligand/ion	26
Water	15
B-factors	
Protein	53.9
Ligand/ion	54.80
Water	45.7
r.m.s.d.	
Bond lengths (Å)	0.01
Bond angles (°)	1.283

r.m.s.d., root mean squared deviation; SAD, single-wavelength anomalous dispersion.
 $R_{\text{sym}} = \sum |I_i - \langle I \rangle| / \sum I_i$ where I_i is the intensity of the *i*th measurement, and $\langle I \rangle$ is the mean intensity for that reflection.
 $R_{\text{work}} = \sum |F_{\text{obs}} - F_{\text{calc}}| / \sum |F_{\text{obs}}|$ where F_{calc} and F_{obs} are the calculated and observed structure factor amplitudes, respectively.
 R_{free} = as for R_{work} , but for 10.0% of the total reflections chosen at random and omitted from refinement. Individual B-factor refinement was carried out.
*Values in the parenthesis are the highest resolution bin values.




Figure 3 | Structure of the GrIR–GrIAΔ interacting surface. (a) The GrIR dimer is shown in surface representation and GrIAΔ is shown as a cartoon. The interacting residues of GrIAΔ are shown as sticks. **(b)** Final 2Fo–Fc electron density map (contoured at 1σ) for the key residues of GrIAΔ.




Figure 4 | Role of the C-terminal region and the HTH motif region of GrlA in GrlR-GrIA interactions. (a) The binding affinities of MBP-GrIA/MBP-GrIA Δ to GrlR were determined using ITC. Representative ITC profiles are shown. The GrlA proteins used are indicated above each panel. The upper part of each panel shows the thermogram (thermal power versus time) after baseline correction and the bottom part of each panel shows the binding isotherm (normalized heat versus molar ratio of reactants) for each injection. The solid lines in the bottom part of each panel show the fit of the data to a function based on a single class of binding site model. (b) The binding affinities of GrlR to MBP-GrIA/MBP-GrIA Δ with substitutions in the HTH motif region (5M) were determined using ITC (5M refers to substitutions at R53A, R54A, R64A, R65A and K66A). The binding constants (K_a and K_d), number of binding sites (N), enthalpy (ΔH) and entropy (ΔS) are provided in Supplementary Table S1.

of these observations, we proposed that promoter DNA and GrlR would compete for the HTH motif region of GrlA. To test this prediction, we adopted a structure-guided alanine substitution analysis created in the HTH motif region of full-length MBP-GrIA at the following positions: R53, R54, R64, R65 and K66 of the HTH motif and Y78. Electrophoretic mobility shift assays (EMSAs) were performed to study the interaction of the GrlA mutants with a DNA fragment containing the *ler* promoter and regulatory regions (Fig. 6a,b). Mutants with single alanine substitutions at R53, R54, R65 and K66 exhibited mobility shifts that were less than that observed for the WT GrlA, indicating a reduced affinity for DNA. The MBP-GrIA R64A mutant and a double mutant of MBP-GrIA (R65A K66A) failed to interact with DNA (Fig. 6b, lanes 4 and 8). Furthermore, the Y78A mutant formed a shifted complex that was comparable to the WT GrlA-DNA complex (Fig. 6b, lane 7).

To determine whether the addition of GrlR could dissociate MBP-GrIA from the *ler* promoter, a competitive EMSA assay was carried out (Fig. 6c). Under the given experimental conditions, when the concentration of GrlR was increased to $0.3 \mu\text{M}$, the MBP-GrIA-DNA complex dissociated. No mobility shift of the DNA was detected at higher GrlR concentrations ($>0.3 \mu\text{M}$). To verify the formation of the GrlR-GrIA complex, a preformed MBP-GrIA-DNA complex bound to amylose beads was titrated against GrlR and washed with DNA-binding buffer. Beads from each of these stages and washes were simultaneously analysed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and EMSA assay. The EMSA gel analysis showed no apparent shift in the DNA as compared with DNA alone after the MBP-GrIA-DNA complex was titrated with GrlR (Supplementary Fig. S9a, lane 6). SDS-PAGE analysis showed bands corresponding to MBP-GrIA and GrlR in the final beads (Supplementary Fig. S9b, lane 9). These results indicate that DNA bound to MBP-GrIA was replaced by GrlR. Besides, these findings show that GrlR outcompetes with DNA to bind to the GrlA HTH motif.

Next, we sought to verify the ability of DNA to pull out GrlA from the GrlR-GrIA complex. A preformed GrlA-GrlR complex was incubated with increasing concentrations of DNA (P_{ler}) for about 30 min and then analysed using EMSA assay. There was no apparent shift in the DNA incubated with preformed GrlA-GrlR complex compared with the control DNA fragment (Supplementary Fig. S10). These results clearly show the inability of DNA to displace GrlR from the GrlR-GrIA complex.

The GrlR-GrIA Δ complex is functional *in vivo*. We next determined whether the GrlA Δ could form a functional regulatory complex with DNA *in vivo*. To this end, we employed the EPEC-null strain ($\Delta\text{grlRA}::kn$), which contains a *ler-gfp* transcriptional fusion (GY2155), and for which the green fluorescent protein (GFP) expression levels report the activity of the *ler* promoter. This strain was transformed with a plasmid expressing GrlA or GrlA Δ , and the GFP levels were compared by western blot analysis using an antibody directed against GFP. The results show that the activity of the *ler* promoter in the strain expressing the full-length GrlA and GrlA Δ is almost the same, indicating that GrlA Δ is functional *in vivo* (Fig. 7a and Supplementary Fig. S11a). This finding also suggests a negligible role of the last 31 amino acids of GrlA in terms of *ler* promoter binding. The strain expressing both GrlR and GrlA showed less activity as compared with the strain expressing GrlA alone, illustrating the repressive activity of GrlR. Repression by GrlR in the GrlA Δ -expressing strain was comparable with that expressing both GrlR and full-length GrlA (Fig. 7a and Supplementary Fig. S11a).

An additional readout for the functionality of GrlA Δ is the secretion of EspB, which reflects *ler* expression and functionality¹⁹. EspB is a major T3SS effector protein and EspB secretion acts as an indicator for the formation of a functional T3SS²⁰. Our measurements of EspB secretion is in agreement with the data obtained with the *ler-gfp* promoter assay. The secretion assay showed comparable EspB secretion between $\Delta\text{grlRA}::kn$ -null strains supplemented with a plasmid expressing either GrlA Δ or full-length GrlA (Fig. 7b and Supplementary Fig. S11b). Similarly, a comparable amount of EspB was secreted from the mutant expressing GrlRA or GrlRA Δ . Although deletion of the C-terminal region of GrlA resulted in a substantial decrease in the affinity between GrlA and GrlR (Fig. 4a), we did not observe significant phenotypic consequences under the experimental conditions used in this study (Fig. 7a,b and Supplementary Fig. S11a,b). This suggests that as long as the N-terminal region of GrlA is intact, the protein remains functional. The role of the




Figure 5 | Role of the key residues in the HTH motif region in GrlR-GrIA Δ interactions. (a) Pull-down assay to show the binding of GrIA Δ or mutant variants with GrlR. MBP-GrIA Δ proteins were bound to amylose beads, incubated with 6His-GrlR overnight and washed. The eluted proteins were separated by 12.5% SDS-PAGE and the gels stained with Coomassie brilliant blue. The GrlA derivatives employed are indicated above the lanes: MBP-GrIA Δ (R65A K66A), MBP-GrIA Δ (R64A R65A), MBP-GrIA Δ (R53A R54A), WT MBP-GrIA Δ and MBP. **(b)** Pull-down assay to show the binding of GrIA Δ with GrlR or the GrlR mutants. The GrlR mutants employed are indicated above the lanes: GrlR D17A, GrlR N66A, GrlR S18A, GrlR D35A GrlR E60A and WT GrlR. The input washes and final elution of the representative mutants are shown in Supplementary Fig. S4a. The additional bands seen on the SDS-PAGE **(a)** were identified as MBP using peptide mass fingerprint analysis (Supplementary Fig. S4b). Western blot analysis of the pull-down assay **(a,b)** was carried out using anti-MBP and anti-His antibodies (Supplementary Fig. S5a,d). The pull-down results were confirmed in a co-expression, co-purification pETDuet-*grlR-grlA* Δ system and analysed on a 12.5% native gel (Supplementary Figs S6a,b, S7 and S8).

additional interaction from the C-terminal region of GrlA thus remains to be identified.

The key HTH residues are required for GrlA function *in vivo*.

EspB secretion was further used to examine the role of the key HTH residues in the regulatory functions of GrlA. To eliminate the negative regulatory effect of GrlR, we transformed the Δ *grlRA::kn*-null strain with a plasmid expressing GrlA Δ . Bacteria were grown under conditions that favoured positive regulation of the T3SS by GrlA⁵, and the amount of EspB secretion was determined by western blot analysis (Fig. 8a and Supplementary Fig. S11c). Secretion of EspB was elevated when the Δ *grlRA::kn*-null strain was supplemented with GrlA Δ , and GrlA with alanine substitutions at R65 or K66 induced efficient EspB secretion (Fig. 8a and Supplementary Fig. S11c). In contrast, the GrlA Δ R64A mutant failed to induce EspB secretion (Fig. 8a and Supplementary Fig. S11c) as did the GrlA Δ (R65A K66A) double mutant. Taken together, the results show that substitutions in key residues in the GrlA HTH region, which hamper binding to the *ler* regulatory region, elicit a profound effect on the ability of the bacteria to assemble a functional T3SS and thus on the bacterial virulence. These effects are presumably related to reduced activity of the *ler* promoter and consequently reduced expression of some or all of the *LEE* operons.

To more directly test the role of HTH key residues in the activation of the *ler* promoter, we employed the *ler-gfp* promoter assay described above (Fig. 8b and Supplementary Fig. S11d). The EPEC-null strain (Δ *grlRA::kn*), which contains a *ler-gfp* transcriptional fusion (GY2155), was transformed with a plasmid expressing various *grlA* mutants. Substitutions such as R65A and K66A were well tolerated, unlike R54A and R64A, where the activity of the *ler* promoter was reduced substantially. The results from both the secretion assay and the *ler-gfp* promoter assays were thus consistent, validating the importance of the key residues in the HTH motif in mediating the function of GrlA as a positive regulator of *ler* and subsequently as positive regulator of the T3SS biogenesis.

GrlR competes with *flhDC* and *ehxCABD* operons for GrlA binding. We next examined whether the competition between the *ler* promoter region and GrlR for binding to GrlA was unique to

the *ler* regulatory region or a more general mode of operation of the GrlR-GrlA system. To this end, we examined two additional GrlA targets: the *flhDC* and *ehxCABD* promoter regions^{11,14,15}. We performed EMSA assays by incubating MBP-GrlA with a DNA fragment containing the *flhDC* promoter region. The addition of GrlA shifted the DNA, indicating that MBP-GrlA had bound to the promoter region of the *flhDC* operon (Supplementary Fig. S12a). The HTH mutants that were previously shown to alter GrlA binding to the *ler* regulatory region showed a similar pattern of binding to the *flhDC* regulatory region (Supplementary Fig. S12b). A competitive EMSA assay also indicated that the addition of GrlR clearly reduced the interaction of GrlA with the *flhDC* regulatory region, presumably by binding to GrlA and displacing the DNA (Supplementary Fig. S13).

With respect to the *ehxCABD* operon, EMSA assays showed that MBP-GrlA specifically binds to the *ehx* promoter region. Subsequent EMSA experiments using mutant MBP-GrlA showed various amounts of reduction in the mobility shifts, consistent with those seen for GrlA binding to *ler* and *flhDC* promoter regions (Supplementary Figs S14a–c and S15). Cumulatively, our findings suggest that the general mode of operation of the GrlR-GrlA system involves mutually exclusive binding of the GrlA HTH motif with either GrlR or its target DNA.

Discussion

Extensive functional analyses have shown that the GrlR-GrlA is a key regulatory complex involved in the direct or indirect regulation of most virulence genes in AE pathogens, including EPEC, EHEC and *C. rodentium*^{3,4,6,8}. These studies include demonstration of the regulatory role of the GrlR-GrlA system in three independent operons: *LEE1*, *flhDC* and *ehxCABD*^{4,11,21}. GrlA positively regulates the expression of *ler*, the first gene in the *LEE1* operon, which in turn regulates the expression of various downstream genes involved in T3SS biogenesis⁴. In addition to *LEE1*, GrlA is also involved in the positive regulation of *ehx* operons and the negative regulation of the *flhDC* operon (Fig. 1). GrlR binds directly to GrlA and functions as an anti-regulator⁴. However, the molecular details of the regulation of the GrlR-GrlA complex have, until now, remained elusive because of the lack of structural details. Here we close this gap, reporting the




Figure 6 | Interaction of GrIA with the *ler* regulatory region *in vitro*.

(a) EMSA assay for PCR DNA fragments comprising the *ler* regulatory region (*ler* – 275/+217; numbers indicate the number of base pairs upstream and downstream from the functional ATG start codon, respectively) DNA VBP is a non-specific DNA. (b) EMSA assay with substituted MBP-GrIA proteins. PCR DNA fragments comprising the regulatory region (*ler* – 275/+217) were mixed and incubated with 1.0 μ M of purified MBP-GrIA, or with different substituted mutants. Free DNA and protein-DNA complexes were resolved by 5% PAGE and stained with ethidium bromide. The GrIA species used include: WT GrIA, GrIA R53A, GrIA R54A, GrIA R64A, GrIA R65A, GrIA K66A, GrIA Y78A, GrIA R65A K66A and *ler* pr (*ler* – 275/+217). (c) Competitive EMSA assay aimed at testing competition between DNA and 6His-GrIR for binding to MBP-GrIA. PCR DNA fragments comprising the regulatory region (*ler* – 275/+217) were mixed and incubated with 1 μ M purified MBP-GrIA for 15 min, then combined with increasing concentrations (0.0, 0.15, 0.3, 0.45 and 0.6 μ M) of 6His-GrIR for an additional 15 min. The complexes and free DNA were separated on a 5% native polyacrylamide gel and stained with ethidium bromide (*ler* pr: *ler* – 275/+217).

crystal structure of the GrIR-GrIA Δ complex, along with supportive functional studies.

In a previous study, we reported the binding between GrIR and GrIA mediated by the possible interaction of an ⁴⁶EDED⁴⁹ motif




Figure 7 | *In vivo* functionality of GrIR-GrIA Δ asymmetric complex.

(a) Immunoblot analysis using anti-GFP antibodies to compare the expression of GFP via the *ler* promoter. The used strains include a deletion mutant of *grIRA* (control; indicated as GrIR^{-A-}); this mutant complemented with plasmids expressing GrIA, GrIA Δ , GrIRA and GIRA Δ , as indicated above the lanes. All strains contained a compatible GFP-expressing plasmid via the *ler* promoter. (b) Secreted proteins were concentrated from supernatants of bacterial culture grown in DMEM and resolved using 12% SDS-PAGE. These samples were then transferred to a PVDF membrane and analysed using a monoclonal antibody against representative secretory protein EspB. The strains used are as in a, but all lack the GFP-expressing plasmid. Strains are indicated above the lanes as in a.




Figure 8 | *In vivo* analysis of the importance of key HTH motif residues in GrIA-DNA binding.

(a) Secreted proteins were concentrated from supernatants of bacterial culture grown in DMEM and resolved in 12% SDS-PAGE. The samples were then transferred to a PVDF membrane and analysed using polyclonal antiserum against representative secretory protein EspB. The used strains include a deletion mutant of *grIRA* (control) (indicated as GrIR^{-A-}); this mutant complemented plasmids expressing GrIA or different GrIA Δ substitutions, as indicated above the lanes (b). Immunoblot analysis using anti-GFP antibodies to compare the expression of GFP via the *ler* promoter. The used strains are similar to those described in a, with the exception that all contain a compatible GFP expression plasmid via the *ler* promoter. Strains are indicated above the lanes.

of GrIR with the C-terminal region of GrIA⁸. However, we could not confirm this finding in the present complex structure because of the absence of the C-terminal region (aa107–137) of GrIA in the crystallized construct, wherein the majority of GrIA Δ

interactions occurs with one monomer of the dimeric GrIR. Despite this, we were able to verify the binding of full-length GrIA to GrIR using ITC and pull-down experiments (Fig. 4a, Supplementary Fig. S5c and Supplementary Table S1). The ITC experiments indicated that full-length GrIA binds to GrIR with a ~35-fold higher affinity than GrIAΔ. These results suggest the role of the GrIA C terminus in its interaction with GrIR. Despite this difference in affinity, under the employed experimental conditions, GrIAΔ exhibited an activity comparable to full-length GrIA (Fig. 7a,b).

Previous studies of the GrIR–GrIA interaction were performed with glutathione S-transferase-tagged proteins^{8,10}. These studies suggest that the glutathione S-transferase tag might interfere with the interaction, and could be the reason for the complete disruption of GrIA binding with GrIR following alanine substitution in the ⁴⁶EDED⁴⁹ motif in our previous study⁸. To avoid this potential pitfall, the current experiments were carried out using MBP-tagged GrIA. We and others have independently verified that MBP is not involved in the GrIA–GrIR interaction¹⁰.

Here we show that substitutions in the HTH motif of GrIAΔ interfered with GrIR binding, whereas the full-length GrIA with substitutions in the HTH region was able to bind to GrIR probably through its C-terminal region (Figs 4b and 5a, Supplementary Fig. S5c; Supplementary Table S1). Jimenez *et al.*¹⁰ show that GrIAΔ¹ (aa1–100) was able to pull down GrIR, and our observation of two binding sites agrees with this finding. Thus, even though the binding site located to the GrIA C terminus was deleted, these deletion constructs can still pull down GrIR via this alternative binding site located at the HTH region.

Our data shows that GrIR interacts with GrIA to prevent its binding to target DNA. The fact that *grlR* and *grlA* are co-transcribed raises the question that under what conditions GrIA can escape suppression by GrIR and interact with its target DNA. Given the tight GrIR–GrIA mode of interaction and the observation that two GrIR molecules are needed to suppress one GrIA molecule, it can be assumed that GrIA will function as a regulator only when its steady-state level reaches more than half of that for GrIR. The relative steady-state level of the two proteins is controlled by their relative translation rates and stability. Although virtually nothing is known about the first, it is expected that the translation rate would be equal in generating both GrIR bound, as well as free, GrIA. The differential stability and specific GrIR degradation by ClpXP has been previously reported⁶. An additional point of view on this system is that GrIR in complex with GrIA stabilizes GrIA and maintains it in an inactive state that can become functional and rapidly released following an appropriate signal and ClpXP-mediated GrIR degradation.

In conclusion, the present study revealed the molecular structure and mechanism of the GrIR–GrIA complex. GrIR and the promoter regions of *ler*, *flhDC* and *ehxCABD* compete for the HTH motif region of GrIA. GrIR outcompetes with these promoter DNA sequences for GrIA. Regulation of multiple virulence operons by a central heterotrimeric GrIR–GrIA complex would help the pathogen to precisely control the expression of various genes involved in its pathogenesis. By differentially regulating the *ler* and *ehx* operons positively and the *flhDC* operon negatively, GrIR and GrIA coordinate and optimize gene expression by the pathogen during the infection process.

Methods

Plasmid and strain construction. Bacterial strains and plasmids used in this study are listed in Supplementary Table S2. Intact *grlR* and *grlA* genes were PCR-amplified from EHEC EDL933 (ref. 22) chromosomal DNA and cloned into MCS1 (with a 6His tag) and MCS2 of the pETDuet-1 (Novagen, Madison, WI, USA)

vector, respectively. Plasmid pET32-*grlR* was constructed by amplifying the *grlR* gene from EHEC EDL933 chromosomal DNA and cloning into pET32 vector. Plasmid pGEX-*grlA* and pMBP-*grlA* were constructed by amplifying the *grlA* DNA fragments from EHEC EDL933 chromosomal DNA and cloning into pGEX-4T1 (GE Healthcare, Buckinghamshire, UK) and pMAL-c2X (New England Biolabs, Ipswich, MA, USA), respectively. The EPEC *grlRA*-null mutant (*ΔgrlRA::kn*) was constructed by replacing the *grlRA* gene from an EPEC strain with a kanamycin cassette by the one-step method using the λ -recombinase system²³. Site-specific mutations in *grlA* were introduced by overlapping PCR²⁴, which uses complementary oligodeoxyribonucleotide (oligo) primers and the PCR to generate two DNA fragments having overlapping ends. These fragments are annealed, allowing the 3'-overlap of each strand to serve as a primer for the 3'-extension of the complementary strand. The resulting fusion product is amplified further by PCR. Specific mutations in the nucleotide sequence were introduced by incorporating nucleotide changes into the overlapping oligo primers. Each construct was verified by DNA sequencing. To construct pGY1, a DNA fragment containing *P_{LEE1}* and *ler* (starting from position –159 compared with the transcriptional start site) was amplified using specific primers; this amplified fragment was digested by *Xba*I and *Bam*HI and cloned into pIR1 digested by the same enzymes^{20,25}. The null strain (*ΔgrlRA::kn*) transformed with pGY1 was named GY2155.

GrIR–GrIA complex structure determination. pETDuet1-*grlR*-*grlAΔ* plasmid was transformed into *E. coli* BL21 cells and grown in defined M9 medium²⁶ supplemented with 25 mg l^{–1} L-SeMet at 37 °C until the optical density reached 0.6 at 600 nm. A 1-litre culture was induced with 100 μM isopropyl β-D-1-thiogalactopyranoside and grown overnight at 20 °C. Cells were then collected by centrifugation and resuspended in 40 ml of lysis buffer (50 mM Tris-HCl (pH 7.0), 0.2 M NaCl, 1% (w/v) Triton X-100, 5% (w/v) glycerol, 10 mM β-mercaptoethanol) with complete protease inhibitors (Roche Applied Science, Mannheim, Germany). The GrIA–GrIR complex was purified in two steps using Ni-NTA (Qiagen, Valencia, CA, USA), followed by gel filtration (Superdex75, GE Healthcare). The 6His tag remained intact on GrIR. Drops containing 1 μl of protein solution (7 mg ml^{–1}) and 1 μl of reservoir solution were equilibrated by hanging-drop vapour diffusion at 25 °C. The best crystals were grown from 12% PEG 3350, 0.1 M sodium malonate pH 5 and 0.4 M non-detergent sulphobetaines 201, with the protein in 30 mM Tris-HCl (pH 7.0), 200 mM NaCl and 5% (w/v) glycerol. One complex consisted of two GrIR and one GrIAΔ (2:1) molecule in the asymmetric unit, which accounts for a Matthews coefficient of 2.40 Å³ Da^{–1} (ref. 27), corresponding to a solvent content of 49%. Crystals were cryoprotected in the reservoir solution supplemented with 25% glycerol and flash cooled at 100 K. The structure was determined using SeMet-labelled protein crystals by single-wavelength anomalous dispersion²⁸. X-ray diffraction data were collected at beamline 13B1, National Synchrotron Radiation Research Centre (Taiwan), using a Quantum-315r charge-coupled device area detector (ADSC) and processed with HKL2000 (ref. 29). All of the expected eight Se sites of an asymmetric unit were located using the programme Phenix-Autofocus. The phases were further improved by density modification using RESOLVE³⁰, which gave a final overall figure of merit of 0.70. Over 50% of the backbone atoms of the model were built by RESOLVE. The remaining residues were manually built using COOT³¹ and refined with phenix-refine³². Refinement was continued until the R-value converged to 0.18 (*R_{free}* = 0.23) for reflections *I* > *σ* (*I*) to 2.7 Å resolution (Table 1). The model had good stereochemistry, with 99.3% residues falling within the allowed regions of the Ramachandran plot. Subsequently, the importance of the key residues in the HTH motif region was validated by structure-based *in vitro* studies, such as ITC and pull-down assay (see Supplementary Methods).

Analytical ultracentrifugation. The stoichiometric ratio of WT GrIR–GrIA complex was investigated by monitoring their sedimentation properties in sedimentation velocity experiments. Samples (400 μl) were used at A280 nm of 1.0 in 30 mM Tris-HCl (pH 7.0), 200 mM NaCl and 5% glycerol. Sedimentation velocity profiles were collected by monitoring the absorbance at 280 nm. The samples were sedimented at 40,000 r.p.m. at 20 °C in a Beckman Optima XL-I centrifuge (Beckman Coulter Inc., Brea, CA, USA) fitted with a four-hole AN-60 rotor and double-sector aluminium centre pieces, and equipped with absorbance optics. A total of 200 scans were collected and analysed using the Sedfit programme³³.

Circular dichroism spectrometry. Far ultraviolet spectra (260–190 nm) of MBP-GrIA/MBP-GrIAΔ and its substituents were measured using a Jasco J-810 spectropolarimeter (Jasco Europe, Milan, Italy) in phosphate buffer (pH 7.5) at room temperature using a 0.1-cm path length and stoppered cuvettes. Six scans were recorded, averaged and the baseline subtracted.

Isothermal titration calorimetry. MBP-GrIA, MBP-GrIAΔ (with or without substitutions in the HTH motif region) and GrIR were all purified in gel filtration buffer containing 30 mM Tris-HCl (pH 7.0), 200 mM NaCl and 5% glycerol. ITC experiments were carried out using a VP-ITC calorimeter (Microcal, LLC, Northampton, MA, USA) at 25 °C using 0.01 mM protein (MBP-GrIA/MBP-GrIAΔ) in the sample cell and 0.15–0.22 mM GrIR in the injector. All samples were

thoroughly degassed and then centrifuged to remove precipitates. Excluding the first 2- μ l injection, 10- μ l injections were sequentially made in each experiment. Consecutive injections were separated by 5 min to allow the peak to return to baseline levels. ITC data were analysed with a model considering a single class of binding sites implemented in Origin 7.0 (Origin Lab Corp., Northampton, MA, USA) software.

Electrophoretic mobility shift assays. EMSA assays were performed by mixing ~100 ng of DNA (promoter region of *ler* (–275/+217; numbers indicate the number of base pairs upstream and downstream from the functional ATG start codon, respectively), *flhDC* (–455/+223) or *ehxCABD* (–261/+22) with increasing concentrations of purified WT or mutant MBP-GrLA proteins in binding buffer containing 10 mM Tris-HCl (pH 8), 50 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 10 μ g ml^{–1} BSA and 5% glycerol. The primers used to amplify the promoter regions are shown in Supplementary Table S3. Reaction mixtures were incubated for 30 min at room temperature and then separated by electrophoresis on 5% polyacrylamide gels in 0.5 \times Tris-borate-EDTA buffer. DNA bands were stained with ethidium bromide and visualized with a Syngene transilluminator (Syngene, Frederick, MD, USA). For competitive EMSA assays, DNA was incubated with 1 μ M MBP-GrLA for 30 min, followed by the addition of increasing concentrations of His-GrLR for an additional 30 min at room temperature. The complexes were visualized as described above. The formation of GrLR–GrLA complex in the competitive EMSA assay was verified by setting up a 300- μ l amylose-resin-bound MBP-GrLA–DNA-binding reaction for 30 min. A 30- μ l sample was run as input on EMSA assay and SDS–PAGE, and the rest was washed several times with excess DNA-binding buffer before titrating with GrLR. A 30- μ l sample was run after titrating with GrLR followed by washes. The final beads and all other washes along with the initial samples were analysed on both EMSA and SDS–PAGE gels. All the EMSA studies were repeated three times and the results were consistent.

Extracellular protein extraction and detection. Overnight cultures of EPEC strains were grown in DMEM medium (Invitrogen, Carlsbad, CA, USA) and supplemented with 30 μ g ml^{–1} of kanamycin, 40 μ g ml^{–1} streptomycin and 34 μ g ml^{–1} chloramphenicol until the optical density at 600 nm reached 0.8. The cultures were diluted 1:50 into fresh DMEM medium and incubated for 9 h at 37 °C in a shaking water bath at 200 r.p.m. Bacterial cells were centrifuged at 5,500 g for 10 min at 4 °C and the supernatants were passed through a 0.22- μ m filter (Millex, Millipore). The extracellular protein fraction was isolated by trichloroacetic acid precipitation and the protein pellet was washed thrice with –20 °C acetone and then air dried³⁴. Extracellular protein pellets were solubilized in Ready Prep reagent 3 (5 M urea, 2 M thiourea, 2% (w/v) CHAPS, 2% (w/v) SB 3–10, 40 mM Tris and 0.2% (w/v) Bio-Lyte 3/10 ampholyte (Bio-Rad, Hercules, CA, USA)), and stored at –80 °C, as described³⁴. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane. EspB was detected by the addition of diluted anti-EspB (1:2,000) polyclonal antiserum, followed by a 1:5,000 dilution of mouse anti-rabbit IgG horseradish peroxidase (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The PVDF membrane was examined using the SuperSignal WestPico Chemiluminescent substrate (Pierce Biotechnology; Rockford, IL, USA) under the conditions recommended by the manufacturer.

ler-gfp Promoter assay. The plasmid pGY1 contains a transcriptional fusion of the *gfp* to the *ler* gene and its regulatory region²⁰. The plasmid was transformed into the EPEC *grlRA::kn* mutant strain EM3715 to create strain GY2155. EPEC strain GY2155 was then transformed with a compatible, pACYC184-based plasmid, expressing GrLA or GrLAA and various *grlA* mutants. The constructed strains were grown in DMEM overnight as described above. Cells were then collected by centrifugation at 5,500 g for 10 min at 4 °C and resuspended in lysis buffer (1 \times PBS) with complete protease inhibitors (Roche Applied Science). The cells were lysed and centrifuged down at 30,000g for 30 min. Protein concentrations in the supernatant were adjusted and separated on an SDS–PAGE, transferred to a PVDF membrane and subjected to western blotting. GFP was detected by the addition of diluted anti-GFP (1:2,000) rabbit monoclonal antibody (Invitrogen), followed by a 1:5,000 dilution of mouse anti-rabbit IgG horseradish peroxidase (Santa Cruz Biotechnology). The PVDF membrane was examined using the SuperSignal WestPico Chemiluminescent substrate under the conditions recommended by the manufacturer.

References

- Nataro, J. & Kaper, J. Diarrheagenic *Escherichia coli*. *Clin. Microbiol. Rev.* **11**, 142–201 (1998).
- Pennington, H. *Escherichia coli* O157. *Lancet* **376**, 1428–1435 (2010).
- Deng, W. *et al.* Dissecting virulence: systematic and functional analyses of a pathogenicity island. *Proc. Natl Acad. Sci. USA* **101**, 3597–3602 (2004).
- Barba, J. *et al.* A positive regulatory loop controls expression of the locus of enterocyte effacement-encoded regulators *Ler* and *GrLA*. *J. Bacteriol.* **187**, 7918–7930 (2005).
- Bustamante, V. H. *et al.* PerC and GrLA independently regulate *Ler* expression in enteropathogenic *Escherichia coli*. *Mol. Microbiol.* **82**, 398–415 (2011).
- Iyoda, S. *et al.* The GrLR–GrLA regulatory system coordinately controls the expression of flagellar and LEE-encoded type III protein secretion systems in enterohemorrhagic *Escherichia coli*. *J. Bacteriol.* **188**, 5682–5692 (2006).
- Iyoda, S. & Watanabe, H. ClpXP protease controls expression of the type III protein secretion system through regulation of RpoS and GrLR levels in enterohemorrhagic *Escherichia coli*. *J. Bacteriol.* **187**, 4086–4094 (2005).
- Jobichen, C. *et al.* Structure of GrLR and the implication of its EDED motif in mediating the regulation of type III secretion system in EHEC. *PLoS Pathog.* **3**, e69 (2007).
- Jobichen, C. *et al.* Identification and characterization of the lipid-binding property of GrLR, a locus of enterocyte effacement regulator. *Biochem. J.* **420**, 191–199 (2009).
- Jiménez, R., Cruz-Migoni, S. B., Huerta-Saquero, A., Bustamante, V. H. & Puente, J. L. Molecular characterization of GrLA, a specific positive regulator of *ler* expression in enteropathogenic *Escherichia coli*. *J. Bacteriol.* **192**, 4627–4642 (2010).
- Kitagawa, R., Takaya, A. & Yamamoto, T. Dual regulatory pathways of flagellar gene expression by ClpXP protease in enterohaemorrhagic *Escherichia coli*. *Microbiology* **157**, 3094–3103 (2011).
- Fujita, Y. & Taguchi, H. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. *Ther. Deliv.* **3**, 749–760 (2012).
- Deretic, V. Autophagy as an innate immunity paradigm: expanding the scope and repertoire of pattern recognition receptors. *Curr. Opin. Immunol.* **24**, 21–31 (2012).
- Schmidt, H., Beutin, L. & Karch, H. Molecular analysis of the plasmid-encoded hemolysin of *Escherichia coli* O157:H7 strain EDL 933. *Infect. Immun.* **63**, 1055–1061 (1995).
- Welch, R. A. & Pellett, S. Transcriptional organization of the *Escherichia coli* hemolysin genes. *J. Bacteriol.* **170**, 1622–1630 (1988).
- Issartel, J. P., Koronakis, V. & Hughes, C. Activation of *Escherichia coli* prohaemolysin to the mature toxin by acyl carrier protein-dependent fatty acylation. *Nature* **351**, 759–761 (1991).
- Wagner, W., Vogel, M. & Goebel, W. Transport of hemolysin across the outer membrane of *Escherichia coli* requires two functions. *J. Bacteriol.* **154**, 200–210 (1983).
- Holm, L. & Sander, C. Touring protein fold space with Dali/FSSP. *Nucleic Acids Res.* **26**, 316–319 (1998).
- Mellies, J., Elliott, S., Sperandio, V., Donnenberg, M. & Kaper, J. The Per regulon of enteropathogenic *Escherichia coli*: identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (*Ler*). *Mol. Microbiol.* **33**, 296–306 (1999).
- Yerushalmi, G., Nadler, C., Berdichevski, T. & Rosenshine, I. Mutational analysis of the locus of enterocyte effacement-encoded regulator (*Ler*) of enteropathogenic *Escherichia coli*. *J. Bacteriol.* **190**, 7808–7818 (2008).
- Saitoh, T. *et al.* Transcription of the *ehx* enterohemolysin gene is positively regulated by GrLA, a global regulator encoded within the locus of enterocyte effacement in enterohemorrhagic *Escherichia coli*. *J. Bacteriol.* **190**, 4822–4830 (2008).
- Hayward, R. D., Leong, J. M., Koronakis, V. & Campellone, K. G. Exploiting pathogenic *Escherichia coli* to model transmembrane receptor signalling. *Nat. Rev. Microbiol.* **4**, 358–370 (2006).
- Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl Acad. Sci. USA* **97**, 6640–6645 (2000).
- Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. & Pease, L. R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* **77**, 51–59 (1989).
- Friedberg, D., Umanski, T., Fang, Y. & Rosenshine, I. Hierarchy in the expression of the locus of enterocyte effacement genes of enteropathogenic *Escherichia coli*. *Mol. Microbiol.* **34**, 941–952 (1999).
- Doublie, S. Preparation of selenomethionyl proteins for phase determination. *Methods Enzymol.* **276**, 523–530 (1997).
- Matthews, B. Solvent content of protein crystals. *J. Mol. Biol.* **33**, 491–497 (1968).
- Terwilliger, T. & Berendzen, J. Bayesian correlated MAD phasing. *Acta Crystallogr. D Biol. Crystallogr.* **53**, 571–579 (1997).
- Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In *Methods in Enzymology*. Vol. 276, 307–326 (Academic Press 1997).
- Terwilliger, T. SOLVE and RESOLVE: automated structure solution and density modification. *Methods Enzymol.* **374**, 22–37 (2003).
- Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 (2004).

32. Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221 (2010).
33. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. *Biophys. J.* **78**, 1606–1619 (2000).
34. Li, M. *et al.* Comparative proteomic analysis of extracellular proteins of enterohemorrhagic and enteropathogenic *Escherichia coli* strains and their ihf and ler mutants. *Appl. Environ. Microbiol.* **70**, 5274–5282 (2004).
35. Delano, W. L. The PyMOL molecular graphics system. <http://pymol.sourceforge.net> (2002).

Acknowledgements

This work was partially supported by a BMRC grant (WBS R154000461305) from the Agency for Science Technology and Research (A*STAR), Singapore. We acknowledge the National Synchrotron Radiation Research Centre beamline 13B1 of the Taiwan synchrotron facility. I.R. was supported by a grant from the Israeli Science Foundation (ISF). K.Y.L. was supported by a grant from the Natural Science and Engineering Research Council (NSERC) Discovery Grant (372373-2010), Canada and Open Funding Project of the State Key Laboratory of Bioreactor Engineering of China. We acknowledge the assistance provided by Dr Gal Yerushalmi in plasmid construction. A.P. is a graduate scholar in receipt of a research scholarship from the National University of Singapore (NUS).

Author contributions

J.S. conceived and designed the study. A.P. performed cloning, expression, purification crystallization, data collection and biophysical analysis. C.J. and A.P. performed the crystallographic calculations and analysis. E.M. generated the null mutants and *ler-gfp* plasmids. A.V.-C. analysed the ITC data. K.Y.L., Y.K.M. and L.M. were involved in the analysis. A.P., C.J., I.R. and J.S. wrote the paper.

Additional information

Accession code: Coordinates of GrIR:GrIAA complex have been deposited in the Protein Data Bank under accession code 4KT5.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Padavannil, A. *et al.* Structure of GrIR–GrIA complex that prevents GrIA activation of virulence genes. *Nat. Commun.* 4:2546 doi: 10.1038/ncomms3546 (2013).